Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05054803
Other study ID # BST-SCI-02
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date October 13, 2021
Est. completion date January 20, 2024

Study information

Verified date January 2024
Source Banc de Sang i Teixits
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a double-blind, randomized, placebo-controlled, multicenter clinical trial in which 18 patients affected with chronic traumatic incomplete cervical spinal cord injury will be randomized to either the active treatment (2 doses of intrathecal WJ-MSC 3 months apart) or to placebo (2 intrathecal infusions, 3 months apart). Thereafter, patients will be followed-up for 12 months for safety and efficacy assessment.


Description:

Double-blind, randomized, placebo-controlled, multicenter clinical trial that will include 18 patients affected with chronic traumatic incomplete cervical spinal cord injury who will be randomized 1:1, stratified by center, to one of the 2 treatment arms of the study: WJ-MSC / WJ-MSC (at a dose of 1E6 ± 30% live cells / Kg of weight) or Placebo / placebo. Medication will be administered intrathecally at day 1 and at 3 months. The main objective of the trial is to assess safety at a 12-month follow-up. Secondary objectives include the evaluation of efficacy through clinical response, electrophysiological changes, questionnaires of functionality and quality of life, as well as the presence of anti-HLA antibodies and donor cellularity in the cerebrospinal fluid.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date January 20, 2024
Est. primary completion date January 20, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Single spinal cord injury lesion caused by trauma 2. Affected cord segments between C1 and T1, confirmed by magnetic resonance 3. Incomplete lesion (ASIA B, C or D) 4. Chronic disease state (between 1 and 5 years after the injury) 5. Patients from 18 to 70 years of age, both sexes 6. Life expectancy > 2 years 7. Residence near the center during study participation and confidence that the patient will attend the follow-up visits 8. Given informed consent in writing 9. Patient is able to understand the study and its procedures Exclusion Criteria: 1. Mechanic ventilation 2. Penetrating trauma affecting the spinal cord 3. Pregnant woman or without proper anticonceptive measures according to the investigator, or breath feeding 4. Planned spinal surgery within subsequent 12 month after entering the trial 5. Neurodegenerative diseases 6. Significant abnormal laboratory tests that contraindicates patient's participation in the study 7. Neoplasia within the previous 5 years, or without complete remission 8. Patient with communication difficulties 9. Simultaneous participation in another clinical trial or treated with an investigational medicinal product the previous 30 days, that could interfere in the results of the study 10. Previous treatment with and advanced Therapy Medicinal Product (cell therapy) 11. Contraindication for lumbar punction 12. Contraindication or inability to follow a rehabilitation program 13. Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria 14. The patient does not accept to be followed-up for a period that could exceed the clinical trial length

Study Design


Intervention

Drug:
WJ-MSC (XCEL-UMC-BETA)
Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months
Placebo
Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months

Locations

Country Name City State
Spain Complexo Hospitalario Universitario A Coruña (CHUAC) A Coruña
Spain Hospital de Neurorehabilitació Institut Guttmann Badalona Barcelona

Sponsors (4)

Lead Sponsor Collaborator
Banc de Sang i Teixits Academic Research Organization (ARO) - VHIR, Complexo Hospitalario Universitario de A Coruña, Institut Guttmann

Country where clinical trial is conducted

Spain, 

References & Publications (1)

Albu S, Kumru H, Coll R, Vives J, Valles M, Benito-Penalva J, Rodriguez L, Codinach M, Hernandez J, Navarro X, Vidal J. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021 Feb;23(2):146-156. doi: 10.1016/j.jcyt.2020.08.008. Epub 2020 Sep 25. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events Adverse events At 12 month follow-up
Secondary American Spinal Injury Association (ASIA) impairment scale Changes in ASIA score with respect to baseline value as detailed at https://asia-spinalinjury.org/international-standards-neurological-classification-sci-isncsci-worksheet/ At 1, 3, 4, 6 and 12 month follow-up
Secondary Motor evoked potentials Changes in motor evoked potentials score with respect to baseline value. Higher scores mean a better outcome At 6 and 12 month follow-up
Secondary Somatosensory evoked potentials Changes in somatosensory evoked potentials score with respect to baseline value. Higher scores mean a better outcome At 6 and 12 month follow-up
Secondary Electrical pain threshold perception Changes in electrical pain threshold perception score with respect to baseline. Lower scores mean a better outcome At 6 and 12 month follow-up
Secondary Handgrip Strength Will be assessed using a dynamometer. Changes in the score with respect to baseline values. Higher scores mean a better outcome At 6 and 12 month follow-up
Secondary Walking index for spinal cord injury (WISCI II) Changes in the walk test WISCIII score with respect to baseline value. The score ranges from 0 (most severe impairment) to 20 (least severe impairment) At 6 and 12 month follow-up
Secondary Numerical scale for neuropathic pain assessment Changes in the numerical scale for neuropathic pain score with respect to baseline value. Score ranges from 0 (no pain) to 10 (unbearable pain) At 6 and 12 month follow-up
Secondary Modified Ashworth scale for spasticity Changes in the modified Ashworth scale score with respect to baseline value. It is a 5 point numerical scale that graded spasticity from 0 to 4, with 0 being no resistance and 4 being a limb rigid in flexion or extension, and includes a 1+ value. At 6 and 12 month follow-up
Secondary Spinal Cord Independence Measure III (SCIM III) Changes in the SCIM III scale score with respect to baseline value. Score ranges from 0 to 20 with higher scores meaning better outcome. At 6 and 12 month follow-up
Secondary World Health Organization Quality of life questionnaire (WHOQOL-BREF) Changes in the WHOQOL-BREF score with respect to baseline value. It contains contains 26 questions each punctuated from 1 to 5 and assesses the individual's overall perception of quality of life (1 to 5), overall perception of their health (1 to 5) and 4 domains of physical health, psychological, social relationships, environment (0-100 each domain). higher scores denote higher quality of life. At 6 and 12 month follow-up
Secondary Psychological general well-being index (PGWBI) Changes in the PGWBI score with respect to baseline value. Score ranges from 0 to 132, with higher scores meaning a better outcome. At 12 month follow-up
Secondary Hospital Anxiety and Depression Scale (HADS) Changes in the HADS score with respect to baseline value. This is a 14-item self-administered questionnaire containing 2 subscales (one for anxiety and one for depression), with a score range of each subscale from 0-21. Higher score indicates higher anxiety and depression. At 12 month follow-up
Secondary Community Integration Questionaire (CIQ-IG) Changes in the CIQ-IG score with respect to baseline value. Score ranges from 0 to 25, with higher scores meaning a better outcome. At 12 month follow-up
Secondary AntiHLA antibodies in cerebrospinal fluid (CSF) Presence or absence of antiHLA antibodies in the CSF after two WJ-MSC infusions At 7 days and at 1 month follow-up after each infusion
Secondary Detection of donor cells in CSF Short tandem repeat (STR) analysis to detect permanence of donor cellularity (WJ-MsC) in the CSF At 7 days after each infusion
See also
  Status Clinical Trial Phase
Recruiting NCT03680872 - Restoring Motor and Sensory Hand Function in Tetraplegia Using a Neural Bypass System N/A
Not yet recruiting NCT06437548 - Epidural Stimulation for Upper Extremity Function N/A
Completed NCT03385005 - Evaluating Neuromuscular Stimulation for Restoring Hand Movements Early Phase 1
Recruiting NCT02983955 - UPNRIDE Powered Wheelchair for Individuals With Walking Impairment: Evaluation of Safety and Usability N/A
Recruiting NCT05390853 - Active tDCS Versus Sham tDCS for Upper Limb Recovery in Incomplete Tetraplegic Patients N/A
Recruiting NCT03048331 - Functional Electrical Stimulation (FES) and Reconstructive Tetraplegia Hand and Arm Surgery N/A
Not yet recruiting NCT04465825 - Developing Strategies to Optimize the Exercise Response After Tetraplegia. N/A
Completed NCT04383873 - Effectiveness Analysis of Armeo Spring Device as a Rehabilitation Treatment in Spinal Cord Injured Patients N/A
Active, not recruiting NCT05462925 - Prediction of Muscle Responsiveness to FES Therapy N/A
Completed NCT04523636 - Evaluation of Splinting in Tetraplegia N/A
Recruiting NCT04276181 - Combined Nerve and Tendon Transfer for the Restoration of Hand Function in Individuals With Tetraplegia
Recruiting NCT04641793 - BoMI for Muscle Control N/A
Recruiting NCT05863754 - Grasp-Release Assessment of a Networked Neuroprosthesis Device N/A
Withdrawn NCT04142814 - Randomized Controlled Study on T-PEP Versus IPV Method for Lower Respiratory Airways Clearance in Tetraplegic Tracheotomized Spinal Cord Injured Patients N/A
Active, not recruiting NCT03184792 - Transcutaneous Electrical Spinal Stimulation to Restore Upper Extremity Functions in Spinal Cord Injury N/A
Recruiting NCT02329652 - Multi-functional Neuroprosthetic System for Restoration of Motor Function in Spinal Cord Injury N/A
Enrolling by invitation NCT04369131 - Controlling Orthostatic Hypotension in People With Cervical Spinal Cord Injury N/A
Completed NCT06159946 - Access-H20 Faucet for Spinal Cord Injury N/A
Completed NCT03239301 - Robotic-assisted Upper Extremity Training in Spinal Cord Injury Patients N/A
Completed NCT05362422 - PAS for Post-SCI Neuropathic Pain N/A